Clinical stage biopharmaceutical company Galectin Therapeutics Inc. (GALT) grabbed our attention after reaching a new 52-week high of $5.10 on September 9, 2025, during intraday trading. The stock closed the regular session at $4.95, up 6.00%, and continued to climb in after-hours trading, gaining an additional 2.02% to reach $5.05.
We highlighted GALT on December 17, 2024, when the stock was trading around $2.32. Since then, it has climbed to a 52-week high of $5.10 on September 9, 2025, marking a remarkable 119.83% gain from our initial alert. Click here to read our Dec. 17 article.
For comments and feedback contact: editorial@rttnews.com
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.